Nelarabine

Revision as of 19:31, 27 September 2011 by WikiBot (talk | contribs) (Protected "Nelarabine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Nelarabine
File:Nelarabine.svg
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding<25%
MetabolismBy adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Elimination half-life30 minutes (nelarabine)
3 hours (ara-G)
ExcretionRenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H15N5O5
Molar mass297.268 g/mol

WikiDoc Resources for Nelarabine

Articles

Most recent articles on Nelarabine

Most cited articles on Nelarabine

Review articles on Nelarabine

Articles on Nelarabine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nelarabine

Images of Nelarabine

Photos of Nelarabine

Podcasts & MP3s on Nelarabine

Videos on Nelarabine

Evidence Based Medicine

Cochrane Collaboration on Nelarabine

Bandolier on Nelarabine

TRIP on Nelarabine

Clinical Trials

Ongoing Trials on Nelarabine at Clinical Trials.gov

Trial results on Nelarabine

Clinical Trials on Nelarabine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nelarabine

NICE Guidance on Nelarabine

NHS PRODIGY Guidance

FDA on Nelarabine

CDC on Nelarabine

Books

Books on Nelarabine

News

Nelarabine in the news

Be alerted to news on Nelarabine

News trends on Nelarabine

Commentary

Blogs on Nelarabine

Definitions

Definitions of Nelarabine

Patient Resources / Community

Patient resources on Nelarabine

Discussion groups on Nelarabine

Patient Handouts on Nelarabine

Directions to Hospitals Treating Nelarabine

Risk calculators and risk factors for Nelarabine

Healthcare Provider Resources

Symptoms of Nelarabine

Causes & Risk Factors for Nelarabine

Diagnostic studies for Nelarabine

Treatment of Nelarabine

Continuing Medical Education (CME)

CME Programs on Nelarabine

International

Nelarabine en Espanol

Nelarabine en Francais

Business

Nelarabine in the Marketplace

Patents on Nelarabine

Experimental / Informatics

List of terms related to Nelarabine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication.

It is marketed as Arranon by GlaxoSmithKline.

External links

Template:SIB Template:WH Template:WikiDoc Sources